234 results
Page 3 of 12
40-F
EX-99.3
fu3 1btbr
23 Feb 22
Annual report (Canada)
5:20pm
6-K
EX-99.1
c1ugx51q7hj
23 Feb 22
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
4:01pm
6-K
EX-99.1
0sc8cs xrufpbb3u01z
17 Dec 21
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States
4:03pm
6-K
EX-99.1
8dcmb 9ss0mz
15 Dec 21
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
5:15pm
6-K
EX-99.2
33f jsgatsisxn
15 Dec 21
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
5:15pm
SUPPL
p7e as7kvz0i
15 Dec 21
Supplemental materials (foreign)
5:10pm
F-10
jr96for
14 Dec 21
Registration of securities (Canada)
9:43am
SUPPL
m1tsefs2 ou
13 Dec 21
Supplemental materials (foreign)
5:00pm
6-K
EX-99.1
zyqrjq8q9oas1p04
13 Dec 21
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
4:07pm
6-K
EX-99.2
zhnzfe3w1dc3p3v9
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:19am
6-K
EX-99.1
qv0rsm 8ogs5pfgrt7l8
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:19am
6-K
EX-99.1
x0nyi2q7lij0m25
13 Dec 21
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
7:00am
6-K
EX-99.4
9v4zl
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.3
dh3pz0pncujrm7hh
10 Nov 21
Condensed Consolidated Interim Financial Statements of
4:42pm
6-K
EX-99.1
l2b4f4a ex8
10 Nov 21
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
4:30pm
6-K
EX-99.1
8jnbu
1 Nov 21
Bellus Health Inc. 6-K
7:00am
6-K
EX-99.1
m3klqk
23 Sep 21
Topline results from both studies are expected in December 2021
7:00am
6-K
EX-99.1
jncd7e m9
13 Sep 21
BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
7:45am
6-K
EX-99.1
lqu48a3wwipa7ag3zgz
23 Aug 21
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021
7:00am
6-K
EX-99.3
4m77 k5zu
11 Aug 21
Condensed Consolidated Interim Financial Statements of
4:43pm